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Abstract
Background
HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic selec-
tion process may lead to discrepancies between the HER2 status of the primary tumor and
circulating tumor cells (CTCs). This study analyzed the HER2 status of CTCs in patients
with HER2-positive primary breast cancer at the time of diagnosis. Aim of the study was to
assess potential discordance of HER2 status between primary tumor and CTCs, as this
may have important implications for the use of HER2-targeted therapy.
Methods
The number and HER2 status of CTCs out of 30ml peripheral blood were assessed in 642
patients using the CellSearch System (Janssen Diagnostics, USA). The cutoff for CTC posi-
tivity was the presence of at least 1 CTC, and the cutoff for HER2 positivity of CTCs was the
presence of at least 1 CTC with a strong HER2 staining.
Results
258 (40.2%) of the 642 patients were positive for CTCs (median 2; range 1–1,689). 149
(57.8%) of these 258 patients had at least 1 CTC with strong HER2 staining. The presence
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of HER2-positive CTCs was not associated with tumor size (p = 0.335), histopathological
grading (p = 0.976), hormone receptor status (ER: p = 0.626, PR: p = 0.263) or axillary
lymph node involvement (p = 0.430). Overall, 83 (32.2%) of the CTC-positive patients exclu-
sively had CTCs with strong HER2 staining, whereas 31 (12.0%) had only CTCs with nega-
tive HER2 staining. Within-sample variation in the HER2 status of CTCs was found in 86
(57.8%) of the 149 patients with more than 1 CTC.
Conclusion
This study demonstrated that discordance between the HER2 expression of CTCs and that
of the primary tumor frequently occurs in early breast cancer. Future follow-up evaluation
will assess whether this discrepancy may contribute to trastuzumab resistance.
Introduction
The expression of HER2 is a poor prognostic factor and is associated with reduced overall sur-
vival (OS) in patients with breast cancer (BC)[1]. After highly effective HER2-targeted therapy
became available, the outcome of patients with HER2-positive BC significantly improved[2].
However, up to 70% of patients who receive adjuvant HER2-targeted therapy (trastuzumab)
after chemotherapy experience disease progression due to both de novo and acquired resis-
tance[3]. Intratumoral heterogeneity in HER2 gene amplification may occur in 16%-54% of
patients and may explain unexpected failures of adjuvant HER2-targeted therapy[4–6]. These
failures are often associated with an equivocal (2+) HER2 status as assessed using immunohis-
tochemical staining (IHC)[7]. Nevertheless, even tumors with clear HER2 overexpression (as
evidenced by 3+ IHC results or by gene amplification using FISH) may fail to respond to
HER2-targeted therapy[8,9]. Furthermore, the HER2 status of patients may change during dis-
ease progression[10,11], which may alter tumor responses to HER2-targeted therapy.
Reevaluating HER2 expression during disease progression is essential for adjusting the
therapy to the current tumor status. Biopsy has been established for the assessment of HER2
expression in metastatic BC (MBC). Because of the lack of solid tumor tissue (primary tumor
or metastasis) during follow-up in early BC patients, no sufficient marker is currently available.
Determination of the HER2 status can be performed using circulating tumor cells (CTCs) as a
“real-time biopsy” in the peripheral blood of BC patients[12–14]. Additionally in studies that
used the CellSearch1 System, CTCs were found to be highly predictive of the OS and progres-
sion-free survival in MBC[15–17] and early BC[18].
In this study, we compared the HER2 expression of CTCs with that of the primary tumor in
patients with HER2-positive early BC, which was determined after surgical intervention but
before the start of systemic therapy. Differences in HER2 expression may explain unexpected
failures of HER2-targeted therapy and reinforce the need to reevaluate HER2 expression dur-
ing the course of early disease to determine the appropriate use of HER2-targeted therapy.
Patients, materials and methods
Patient population
This study was performed as a predefined translational research project of the SUCCESS B
trial. From 2008–2011, a total number of 793 patients were enrolled in the SUCCESS B trial.
The trial included 129 participating centers in Germany. The SUCCESS B trial was an open-
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label, multicenter, randomized, controlled, phase III study that compared the disease free sur-
vival (DFS) of patients who were treated with 3 cycles of epirubicin-fluorouracil-cyclophos-
phamide (FEC) chemotherapy, followed by 3 cycles of docetaxel (D) chemotherapy every
three weeks (q3w), versus 3 cycles of FEC, followed by 3 cycles of gemcitabine-docetaxel (GD)
chemotherapy q3w. At the end of chemotherapy, all of the patients had received adequate anti-
HER2 treatment according to the study protocol. Eligible patients were confirmed to have
HER2-positive invasive early BC with histopathological proof of axillary lymph node metasta-
ses (pN1-3) or high-risk node-negative disease, which was defined as a pT 1c, a histopatho-
logical grade 2, an age 35 years or a negative hormone receptor status. Categorization of
the tumor stage at primary diagnosis was performed according to the tumor node metastasis
(TNM) classification system that was revised by the American Joint Committee on Cancer
(AJCC)[19].
Determination of the phenotype of the primary tumor was performed at each local labora-
tory of pathology according to the ASCO/CAP criteria for hormone receptor and HER2 deter-
mination using IHC (3+) or fluorescence in situ hybridization (FISH). The phenotypic results
were obtained from the laboratory reports. All of the patient data were collected from a central
database and exported after several data cleaning steps were performed at the beginning of
2013.
Patients were enrolled in the study no later than 6 weeks after the complete resection of the
primary tumor. Written informed consent to participate in the SUCCESS B trial was obtained
from all of the patients. The trial was approved by the ethical committee of Ludwig-Maximi-
lians-University, Munich, Germany (EudraCT Number 2007-001094-29) and listed at Clini-
calTrials.gov (NCT00670878). This trial was conducted according to the most recent version
of the Declaration of Helsinki and the International Conference on Harmonization Good
Clinical Practice Guideline, 1998.
CTC detection
As part of the translational research project of this trial, we drew peripheral blood from the
trial participants that provided written informed consent for the adjunct translational research
program (not mandatory for recruitment in the SUCCESS B study) before the start of adjuvant
chemotherapy. A total of 30 ml of blood was taken for the detection of CTCs. The semi-auto-
mated CellSearch1 System (Janssen Diagnostics, LLC, USA), which consists of the Cell-
Tracks1 AutoPrep1 System and the CellTracks1 Analyzer II1, was used for the isolation
and enumeration of CTCs. This CTC detection method is based on the use of antibody-coated
magnetic beads for the immunomagnetic isolation of tumor cells that express the epithelial-
cell adhesion molecule (EpCAM). This method has been previously published[15]. In brief,
the blood samples were drawn into CellSave tubes (3 x 10 ml) that contained a cell preservative
and EDTA. After shipment at room temperature, the samples were analyzed within 96 hours
of collection at the central cancer immunological laboratory at the University of Munich. The
blood of three CellSave tubes was pooled (for more information about the pooling step please
refer to the detailed description provided as S1 File). After pooling, the blood was centrifuged
for 10 minutes at 800 x g and a dilution buffer was added after the plasma was removed. In a
syringe with a valve and tubing, this mixture was overlaid on 6 ml of Histopaque (Sigma, Ger-
many) and centrifuged for 10 minutes at 400 x g. Subsequently, the CellTracks AutoPrep Sys-
tem and the CellSearch Epithelial Cell Kit (Janssen Diagnostics, USA) were used to process 7.5
ml of sample that contained the buffy coat and mononuclear cells. The CTCs were labelled
with the fluorescent nucleic acid dye 4,2-diamidino-2-phenylindole dihydrochloride to stain
the nuclei. Fluorescently labelled monoclonal antibodies that were specific for epithelial cells
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(cytokeratin 8,18,19-phycoerythrin) and leukocytes (CD45-allophycocyanin) were used to dis-
tinguish between these cell types. CTC identification was performed by two independent
trained individuals using the CellTracks Analyzer II, a semiautomated fluorescence-based
microscopy system. Nucleated cells that lacked CD45 and expressed cytokeratin were defined
as tumor cells. Additional morphological criteria, i.e., a round or oval shape and a size 5 μm,
were considered. A recent analysis demonstrated the good accuracy, precision, linearity, and
reproducibility of the system[20].
Out of 694 blood samples available for analysis, 28 samples could not be analyzed due to
technical problems with the CellSearch1 System, and 24 probes could not be evaluated
because of a lack of sufficient amounts of blood (7.5 ml was the minimum amount required as
established for MBC). Thus, we obtained valid measurements for the number and HER2 status
of CTCs from 642 patient samples. Fig 1 illustrates the patient selection process for this study.
Determination of the HER2 status of CTCs
FITC-labeled anti-HER2 antibodies were used to further characterize the HER2 expression of
CTCs using the CellSearch System according to the manufacturer’s instructions (CellSearch
tumor phenotyping reagent HER2; Janssen Diagnostics). The HER2 status of the CTCs was
determined according to specific criteria by Riethdorf et al. To establish a standard for HER2
immunostaining, Riethdorf et al. spiked blood samples from healthy donors with approxi-
mately 500 breast cancer cells from cell lines with a known HER2 status (MCF-7, BT20, T47D,
SK-BR-3, BT474 and MDA-MB-453) and processed these cells using the CellSearch System. In
parallel, these cell lines were analyzed using immunocytochemistry and FISH to detect HER2
expression. HER2 gene amplification was determined by FISH, which counted the HER2 and
centromere 17 signals. The ratio between the mean numbers of HER2 and centromere 17 sig-
nals determined the HER2 gene amplification. Riethdorf et al. distinguished between negative
(-), weak (+), moderate (++) and strong (+++) HER2 staining according to the matched cell
lines that were known to express HER2 and were correlated with the FISH analysis[21].
Using these criteria, only CTCs with a strong (+++) HER2 signal were defined as HER2-po-
sitive in this study. The cutoff for CTC positivity was the presence of at least 1 CTC per 30 ml
of blood, and the cutoff for HER2 positivity in CTCs was the presence of at least 1 CTC with a
strong (+++) HER2 signal.
Statistical analysis
Descriptive statistics for all of the categorical data are summarized in frequency tables that
present the absolute and relative frequencies, whereas the continuous but not normally distrib-
uted variables are described using median and range. Associations between the patient and
tumor characteristics and the presence of CTCs and HER2-positive CTCs were analyzed using
the chi-squared test. To assess which patient and/or tumor characteristics predict the presence
of HER2-positive CTCs, we used a multivariate logistic regression model with presence of
HER2-positive CTCs (yes/no) as binary response variable. The Cochran-Armitage test for
trend was used to test for an association between the number of CTCs in a sample and the
presence of HER2-positive CTCs. The correlation between the number of CTCs that were
detected in a sample and the percentage of HER2-positive CTCs in that sample was analyzed
using Spearman’s rank correlation coefficient. Finally, the binomial test was used to compare
the proportions of HER2-positive and HER2-negative CTCs in patients with one CTC only.
All of the reported p-values were two-tailed, and all of the calculations were performed using
IBM SPSS Statistics (IBM Corp. Released 2010. IBM SPSS Statistics for Windows, Version
19.0. Armonk, NY).
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Results
Prevalence of CTCs in patients with HER2-positive early BC
Valid measurements of the presence and HER2 status of CTCs before adjuvant chemotherapy
were available for 642 patients. Of these patients, 258 (40.2%) were positive for CTCs (median
= 2; range 1–1,689): 109 patients (42.2%) had one CTC, 65 patients (25.2%) had two CTCs, 38
patients (14.7%) had three CTCs, 12 patients (4.7%) had four CTCs, and 34 patients (13.2%)
had five or more CTCs. Approximately half of the patient population had a pT1 tumor. Over-
all, 43% of the patients had lymph node involvement and the majority of patients had high-
Fig 1. Flow chart illustrating study flow and patient selection.
https://doi.org/10.1371/journal.pone.0173593.g001
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grade (G3) tumors. Of all the patients, 59% and 53% had a positive estrogen receptor (ER) or
positive progesterone receptor (PR) status, respectively. No significant association was
observed between the presence of CTCs and any of the clinicopathological parameters that
were investigated (chi-squared test, all p> 0.05; see Table 1).
Table 1. Associations between presence of CTCs, patient characteristics and clinicopathological characteristics of the primary tumor.
Clinical variable at baseline Total N = 642 (%) CTC-negative N = 384 CTC-positive N = 258 P-value
pT 0.480
1 310 (48.3%) 190 (49.5%) 120 (46.5%)
2 273 (42.5%) 154 (40.1%) 119 (46.1%)
3 25 (3.9%) 16 (4.2%) 9 (3.5%)
4 9 (1.4%) 4 (1.0%) 5 (1.9%)
missing 25 (3.9%) 20 (5.2%) 5 (1.9%)
pN 0.510
0 339 (52.8%) 204 (53.1%) 135 (52.3%)
+ (1,2,3) 278 (43.3%) 160 (41.7%) 118 (45.7%)
missing 25 (3.9%) 20 (5.2%) 5 (1.9%)
Histology 0.235
Ductal 232 (36.1%) 128 (33.3%) 104 (40.3%)
lobular 23 (3.6%) 12 (3.1%) 11 (4.3%)
Other 360 (56.1%) 222 (57.8%) 138 (53.5%)
missing 27 (4.2%) 22 (5.7%) 5 (1.9%)
Grading 0.780
1 7 (1.1%) 5 (1.3%) 2 (0.8%)
2 230 (35.8%) 136 (35.4%) 94 (36.4%)
3 375 (58.4%) 219 (57.0%) 156 (60.5%)
missing 30 (4.7%) 24 (6.3%) 6 (2.3%)
ER status 0.924
negative 237 (36.9%) 140 (36.4%) 97 (37.6%)
positive 380 (59.2%) 223 (58.1%) 157 (60.9%)
missing 25 (3.9%) 21 (5.5%) 4 (1.6%)
PR status 0.986
negative 272 (42.4%) 160 (41.7%) 112 (43.4%)
positive 343 (53.4%) 202 (52.6%) 141 (54.7%)
missing 27 (4.2%) 22 (5.7%) 5 (1.9%)
Menopause 0.340
pre-menopausal 242 (37.7%) 139 (36.2%) 103 (39.9%)
post-menopausal 400 (62.3%) 245 (63.8%) 155 (60.1%)
Age (years) 0.061
< 50 231 (36.0%) 127 (33.1%) 104 (40.3%)
 50 411 (64.0%) 257 (66.9%) 154 (59.7%)
Chemotherapy 0.922
FEC-DG 317 (49.4%) 189 (49.2%) 128 (49.6%)
FEC-D 325 (50.6%) 195 (50.8%) 130 (50.4%)
pT, pN, Histology, Grading, ER status, PR status tested using valid categories only (without missing information)
FEC-DG = epirubicin-fluorouracil-cyclophosphamide/gemcitabine-docetaxel chemotherapy
FEC-D = epirubicin-fluorouracil-cyclophosphamide docetaxel chemotherapy
https://doi.org/10.1371/journal.pone.0173593.t001
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HER2 phenotype of CTCs and patient characteristics
The HER2 status of CTCs was assessed for all 258 CTC-positive patients. Of these patients, 149
(57.8%) had at least one CTC with strong (+++) HER2 staining; therefore, these patients were
classified as having HER2-positive CTCs according to our cutoff criterion. Of the CTC-posi-
tive patients, 109 (42.2%) had no CTCs with strong HER2 staining: 55 (21.3%) had at least one
CTC with moderate (++) HER2 staining, 23 (8.9%) had no CTCs with moderate (++) HER2
staining but at least one CTC with weak (+) HER2 staining, and 31 (12.0%) were exclusively
HER2-negative (-) CTC (Fig 2).
Univariate analyses revealed no association between the presence of HER2-positive CTCs
and tumor size, histopathological grading, hormone receptor status or axillary lymph node
involvement (chi-squared test, all p> 0.05; see Table 2). However, pre-menopausal patients
were more likely to have HER2-positive CTCs than post-menopausal patients (chi-squared test,
χ2 = 4.8, p = 0.028), and patients with ductal or lobular invasive breast cancer were less likely to
have HER2-positive CTCs than patients with other histological types of BC (chi-squared test,
χ2 = 6.08, p = 0.048). These results were largely confirmed by a multivariate logistic regression
analysis with presence of HER2-positive CTCs (yes/no) as binary response variable (see Table 3).
Prevalence of HER2-positive CTCs in relation to the CTC count
The probability of detecting at least one HER2-positive CTC increased with the number of
detected CTCs (1, 2, 3, 4, or more than 4 CTCs detected; Cochran-Armitage test for trend,
p = 0.0013; see Fig 3). However, no significant correlation was detected between the number of
CTCs in a sample and the percentage of HER2-positive CTCs among these CTCs (Spearman’s
rank correlation coefficient rs = -0.07, p = 0.264).
Between-sample and within-sample variability in the HER2 status of
CTCs
Detailed data on the between-sample and within-sample variation in the HER2 staining inten-
sities of CTCs are presented in Table 4 and Fig 4. Overall, 56 out of 109 patients (51%) with
Fig 2. The distribution of samples (n = 642) according to CTC status and the highest HER2 staining
intensity of CTCs in the samples.
https://doi.org/10.1371/journal.pone.0173593.g002
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only one detected CTC had an HER2-positive CTC (i.e., strong (+++) HER2 staining), and 53
patients (49%) had no HER2-positive CTC status (i.e. moderate, weak, or negative HER2 stain-
ing). Hence, patients with only one CTC were not more likely to have an HER2-positive CTC
than a not HER2-positive CTC (Binomial test, p = 0.85). Furthermore, 27 of the 149 patients
Table 2. Associations between presence of HER2-positive CTCs, patient characteristics and clinicopathological characteristics of the primary
tumor.
Clinical variable at baseline CTC-positive (N = 258) P-value
Only HER2-negative CTCs N = 109 At least one HER2-positive CTC N = 149
pT 0.335
1 51 (46.8%) 69 (46.3%)
2 48 (44.0%) 71 (47.7%)
3 3 (2.8%) 6 (4.0%)
4 4 (3.7%) 1 (0.7%)
missing 3 (2.8%) 2 (1.3%)
pN 0.430
0 54 (49.5%) 81 (54.4%)
+ (1,2,3) 53 (48.6%) 65 (43.6%)
Missing 2 (1.8%) 3 (2.0%)
Histology 0.048
Ductal 50 (45.9%) 54 (36.2%)
Lobular 7 (6.4%) 4 (2.7%)
Other 49 (45.0%) 89 (59.7%)
Missing 3 (2.8%) 2 (1.3%)
Grading 0.976
1 1 (0.9%) 1 (0.7%)
2 40 (36.7%) 54 (36.2%)
3 66 (60.6%) 90 (60.4%)
Missing 2 (1.8%) 4 (2.7%)
ER status 0.626
negative 39 (35.8%) 58 (38.9%)
positive 68 (62.4%) 89 (59.7%)
missing 2 (1.8%) 2 (1.3%)
PR status 0.263
negative 43 (39.4%) 69 (46.3%)
positive 64 (58.7%) 77 (51.7%)
missing 2 (1.8%) 3 (2.0%)
Menopause 0.028
pre-menopausal 35 (32.1%) 68 (45.6%)
post-menopausal 74 (67.9%) 81 (54.4%)
Age (years) 0.205
< 50 39 (35.8%) 65 (43.6%)
 50 70 (64.2%) 84 (56.4%)
Chemotherapy 0.201
FEC-DG 49 (45.0%) 79 (53.0%)
FEC-D 60 (55.0%) 70 (47.0%)
pT, pN, Histology, Grading, ER status, PR status tested using valid categories only (without missing information)
FEC-DG = epirubicin-fluorouracil-cyclophosphamide/gemcitabine-docetaxel chemotherapy
FEC-D = epirubicin-fluorouracil-cyclophosphamide docetaxel chemotherapy
https://doi.org/10.1371/journal.pone.0173593.t002
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with more than one CTC exclusively had HER2-positive CTCs; therefore, 83 (32.2%) out of
258 patients with CTCs exclusively had HER2-positive CTCs.
Of these 258 patients, 67 (26.0%) had at least one CTC with negative HER2 staining and 31
(12.0%) patients exclusively had HER2-negative CTCs. The majority of these patients had only
1 CTC (n = 19); however, 8 patients had 2–3 CTCs and the remaining patients (n = 4) had 6,
110, 120, and 1,689 CTCs (see Table 4).
Of the 149 patients with more than one CTC, 63 (42.3%) had CTCs with similar HER2
staining intensities and no variation was detected in the HER2 status of the CTCs in these
patients. Therefore, within-sample variation in the HER2 staining intensities of CTCs was
observed in 86 patients: 62 patients had CTCs with two different HER2 staining intensities,
20 patients had CTCs with three different HER2 staining intensities, and 4 patients had CTCs
with four different HER2 staining intensities. Among the 149 patients with more than one
CTC, 28 (18.8%) had at least one CTC with negative HER2 staining and at least one CTC with
strong HER2 staining (see Table 4 and Fig 4).
Discussion
We investigated the HER2 expression of CTCs in the peripheral blood of patients with HER2-
positive early BC before the start of systemic treatment but after the complete surgical resection
of the PT. We did not detect any HER2-positive (+++) CTCs in 42.2% of the CTC-positive
blood samples. Overall, 12.0% of patients had HER2-negative (-) CTCs. In addition, 26% of
Table 3. Results of a multivariate logistic regression model with presence of HER-positive CTCs (yes/no) as binary response variable (n = 248
patients; 10 patients were excluded from the multivariate analysis because of missing values).
Clinical variable at baseline Odds ratio 95% Confidence interval P-value
pT 0.370
pT2 vs. pT1 0.15 0.67–1.98 0.612
pT3 vs. pT1 2.26 0.44–11.58 0.328
pT4 vs. pT1 0.21 0.02–2.03 0.177
pN 0.541
pN+ vs pN0 0.85 0.49–1.45 0.541
Histology 0.036
lobular vs. ductal 0.41 0.10–1.75 0.229
other vs. ductal 1.73 1.00–3.01 0.052
Grading 0.913
G2 vs. G1 0.73 0.04–14.24 0.835
G3 vs. G1 0.66 0.03–12.92 0.782
ER status 0.710
positive vs. negative 1.16 0.53–2.52 0.710
PR status 0.337
positive vs. negative 0.69 0.32–1.48 0.337
Menopause 0.087
post- vs. pre- menopausal 0.47 0.20–1.12 0.087
Age (years) 0.634
 50 vs. < 50 1.23 0.52–2.92 0.634
Chemotherapy 0.166
FEC-D vs. FEC-DG 0.686 0.40–1.17 0.166
FEC-DG = epirubicin-fluorouracil-cyclophosphamide/gemcitabine-docetaxel chemotherapy
FEC-D = epirubicin-fluorouracil-cyclophosphamide docetaxel (D) chemotherapy
https://doi.org/10.1371/journal.pone.0173593.t003
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patients had at least 1 HER2-negative (-) CTC, and only 32.2% of patients exclusively had
HER2-positive (+++) CTCs. Within-sample variation in the HER2 staining intensities of CTCs
was observed in 86 (58%) out of 149 patients with more than one CTC. In several samples, the
differences in the HER2 staining intensities were remarkable: 28 (18.8%) out of 149 patients
with more than one CTC had at least one CTC with negative HER2 staining and at least one
CTC with strong HER2 staining. Furthermore, pre-menopausal patients were more likely to
have HER2-positive (+++) CTCs than post-menopausal patients, and patients with ductal or
other types of invasive BC were more likely to have HER2-positive (+++) CTCs than patients
with the lobular type of BC. Therefore, considerable discordance was found between the HER2
status of the primary tumor and CTCs in early BC. To the best of our knowledge, this study is
the largest and most comprehensive to date on the HER2 status of CTCs before adjuvant
chemotherapy.
Different approaches are available to enrich and detect CTCs and their phenotype. In this
study, we used the CellSearch1 System, which is based on immunomagnetic enrichment
using EpCAM antibodies and immunofluorescence detection with different antibodies. This
system is the most widely used device for CTC detection and was approved by the FDA in
2004 for CTC counting in the management of MBC treatment. The system is associated with
high recovery rates and precision even at low cell levels[22]. However, there is currently no
standardized and widely accepted method to determine the HER2 status of CTCs. We per-
formed HER2 determination of CTCs using the CellSearch1 System according to predefined
criteria by Riethdorf et al., which were based on extensive validation experiments that used
breast cancer cell lines with a known HER2 gene amplification status (as previously described)
[21].
We detected CTCs in 258 (40.2%) patients with early BC before the start of adjuvant che-
motherapy. This detection rate is higher than that in our previous findings (21.5% in the adju-
vant setting)[18]. However, the patient sample in our previous study comprised patients with
HER2-positive and HER2-negative BC, whereas this study only included patients with
Fig 3. The prevalence of HER2-positive CTCs (i.e., CTCs with strong HER2 staining) in relation to the
number of CTCs detected in the blood samples (n = 258).
https://doi.org/10.1371/journal.pone.0173593.g003
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HER2-positive BC. Therefore, HER2 overexpression by the primary tumor may trigger the
prevalence of CTCs, which may be a reason for this discrepancy[23,24].
Using the CellSearch1 System, Fehm et al. reported that 42% of patients with HER2-posi-
tive MBC exclusively had HER2-negative CTCs and 32% of patients with HER2-negative MBC
had HER2-positive CTCs in their peripheral blood[25]. Riethdorf et al. detected HER2-nega-
tive and weakly HER2-positive CTCs in 11 of 21 patients with HER2-positive BC before and
after the start of neoadjuvant chemotherapy[21]. The data from our study indicate that many
CTCs that were detected in patients with HER2-positive early BC before the start of adjuvant
chemotherapy did not express HER2. Samples with 5 CTCs or more may not have had any
HER2-positive (+++) CTCs or may have exclusively contained HER2-negative (-) CTCs.
Different methods to determine the HER2 status of CTCs have produced comparable
results. Using simultaneous immunofluorescence staining of CK, ER and HER2 after the prep-
aration of glass slides, Rack et al. demonstrated that CTCs may have a different hormone and
HER2 status than the primary tumor[26]. Georgoulias et al. detected CK19 mRNA-positive
CTCs using RT-PCR. Additional immunofluorescence double-staining for CK and HER2
revealed HER2-expressing CTCs in 89% of patients with HER2-negative early BC[27]. Using
the AdnaTest, which is based on immunomagnetic cell selection, followed by multiplex PCR,
Fehm et al. found that the concordance rates between the ER, PR and HER2 status of CTCs
and that of the primary tumor in early BC were 29%, 25% and 53%, respectively[28]. Krishna-
murthy et al. evaluated a microfluidic platform for detecting HER2 gene amplification using
FISH and CTCs from patients with early BC. These authors detected discordance between the
HER2 status of the primary tumor and that of the CTCs in 15% of the patients[29]. In this
study, 42% (109 out of 258 CTC-positive patients) of the patients with HER2-positive early BC
had no HER2-positive (+++) CTCs. Therefore, irrespective of the method used, a high discor-
dance rate in the HER2 expression between the primary tumor and CTCs was found in all of
these studies.
Intratumoral heterogeneity in HER2 expression may explain unexpected failures of HER2--
targeted therapy with trastuzumab[30]. Ohlschlegel et al. demonstrated that HER2 heterogene-
ity frequently occurred in breast cancer according to the ASCO/CAP definition and occurred
Table 4. Between-sample and within-sample variability in the HER2 status of CTCs in patients with early HER2-positive breast cancer.
Profile of the HER2 status of CTCs (the number of different HER2 staining
intensities in the CTCs of a patient)
One HER2
staining
intensity
Two HER2 staining
intensities
Three
HER2
staining
intensities
Four HER2 staining
intensities
HER2 status of CTCs (HER2 staining
intensity)
- (negative) + + + + + + + +
+ (weak) + + + + + + + +
++ (moderate) + + + + + + + +
+++ (strong) + + + + + + + +
Number of CTCs detected 1 (n = 109) 19 15 19 56
2 (n = 65) 4 6 14 13 2 2 6 6 2 10
3 (n = 38) 4 3 10 1 3 3 1 9 1 1 2
4 (n = 12) 1 2 1 1 3 2 1 1
5 or more
(n = 34)
4 2 2 2 1 7 2 2 6 3 3
Total (n = 258) 31 21 37 83 2 4 11 12 4 29 2 5 8 5 4
https://doi.org/10.1371/journal.pone.0173593.t004
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most often in carcinomas with equivocal (2+) IHC results for HER2[7]. By studying different
areas of one tumor, the discordance rates of HER2 amplification among the analyzed samples
ranged from 36% to 54%[6],[31]. Primary tumors with HER2 heterogeneity may shed CTCs
with different HER2 staining levels which may explain our findings. The primary tumors of
our patient collective were tested for HER2 amplification according the ASCO/CAP criteria
and fulfilled the criteria for HER2-targeted therapy. In clinical routine though the primary
tumor is not tested for HER2 heterogeneity. Therefore CTCs may give an even more precise
picture of the actual HER2 status of one patient.
Few studies have demonstrated the effects of HER2-targeted therapies on the number of
detected CTCs[27,32]. However, no data are available on the effect of HER2-targeted therapies
on the HER2 status of CTCs. This issue will be addressed in ongoing trials that are focusing on
personalized treatment that is based on the HER2 phenotype of CTCs and the effect of targeted
therapies on the number and phenotypes of CTCs. The DETECT III trial is currently investi-
gating an HER2-targeted therapy (lapatinib) in patients with HER2-negative MBC but HER2--
positive CTCs. In the adjuvant setting, the Treat CTC trial will evaluate the effect of an
HER2-targeted therapy with trastuzumab on CTC load in patients with persistent CTCs after
adjuvant chemotherapy,[33] irrespective of the HER2 status of CTCs.
Our study focused on a highly relevant topic of research; however, there are several limita-
tions to this study. Detecting the HER2 status of CTCs remains the focus of ongoing investiga-
tion. There are currently no fully automated methods for determining the HER2 status of
CTCs, and the final evaluation of HER2 status in this study was based on the subjective inter-
pretation of the investigator. Furthermore, a high degree of discordance (26%) was found in
the HER2 testing of the solid tumor tissue between local and central laboratories. The need to
use high-volume, experienced laboratories for HER2 testing is supported by the high degree of
agreement (89.1%) between central and reference laboratories[34]. Therefore, our findings
may have been affected by the lack of reliability in the HER2 testing of the primary tumor.
Fig 4. The frequency and percentage (out of 258 CTC-positive samples) of samples with selected
characteristics regarding the HER2 status of CTCs.
https://doi.org/10.1371/journal.pone.0173593.g004
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Additionally, the CTC detection rate was low (20%-40%)[18,21,35] in the neo-/adjuvant
setting compared with that in the metastatic setting (50%-80%)[15,17,36]. In several studies of
patients with early BC, only one CTC could be detected in the majority of the blood samples
[18,21,37], which makes the evaluation of the HER2 status of CTCs even more challenging.
Therefore, we pooled three CellSave tubes to reach a total volume of 30ml to increase the
detection rate and the sensitivity.
Furthermore, these are data describing the prevalence of CTCs only. Prognostic influence
of CTCs in early HER2-positive BC will be presented as soon as the follow up within the SUC-
CESS B trial will be completed.
Conclusion
In conclusion, this study is the largest to date that has evaluated the HER2 status of CTCs
before adjuvant chemotherapy. This study found that the HER2 status of CTCs may differ
from the HER2 status of the primary tumor in patients with early HER2-positive BC. Our
results strongly suggest that the HER2 status of patients needs to be reassessed to correctly
determine the appropriate use of HER2-targeted therapy. Ongoing trials are evaluating the
phenotype and molecular characterization of CTCs as a basis for decision-making in targeted
drug development and individualized treatment.
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